Navidea Biopharma shares fall after negative report on Lymphoseek(Reuters) - Navidea Biopharmaceuticals Inc's shares fell as much as 17 percent on Friday after a negative report on TheStreet.com despite the company receiving expanded U.S. approval for its imaging agent. The U.S. Food and Drug Administration on Friday approved Navidea's imaging agent, Lymphoseek, to help physicians determine the extent of head and neck cancer. Lymphoseek was approved in the United States last year in injectable form in patients with breast cancer or melanoma.
Source: Navidea Biopharma shares fall after negative report on Lymphoseek (http://news.yahoo.com/navidea-biopharma-shares-fall-negative-report-lymphoseek-174922181--finance.html)